Compounds > cheliensisin a
Page last updated: 2024-11-13

cheliensisin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cheliensisin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56683717
CHEMBL ID1818734
SCHEMBL ID15937093
MeSH IDM0490958

Synonyms (3)

Synonym
cheliensisin a
CHEMBL1818734
SCHEMBL15937093

Research Excerpts

Overview

Cheliensisin A is a natural styryl-lactone isolated from Goniothalamus cheliensis Hu. It has putative anticancer activities.

ExcerptReferenceRelevance
"Cheliensisin A is a natural styryl-lactone isolated from Goniothalamus cheliensis Hu in considerably large quantity with putative anticancer activities. "( Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
Deng, X; Li, Y; Peng, LY; Su, J; Yao, ZJ; Zhao, QS; Zhao, Y, 2011)		2.05

Dosage Studied

ExcerptRelevanceReference
" However, due to its poor water solubility and chemical instability, choosing the appropriate dosage form is of great significance."( Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect.
Fu, Y; Gong, T; He, LL; Liu, J; Nie, Y; Zhang, ZR; Zhao, D, 2008)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID613816Cytotoxicity against human A549 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613814Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613817Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613818Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613819Chemical stability of the compound in 0.1 M phosphate buffer at pH 7.0 at 0.1 mg/mL after 12 hrs by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613815Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.110L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
h 89
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.		2.0210N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.4920
ConditionIndicatedRelationship StrengthStudiesTrials
Bladder Cancer
[description not available]		07.5520
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.5520
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.4920
Cancer of Colon
[description not available]		02.4720
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4720
Cancer of Lung
[description not available]		02.0410
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0410